JPS5982313A - 体内脂質減少剤 - Google Patents
体内脂質減少剤Info
- Publication number
- JPS5982313A JPS5982313A JP19236282A JP19236282A JPS5982313A JP S5982313 A JPS5982313 A JP S5982313A JP 19236282 A JP19236282 A JP 19236282A JP 19236282 A JP19236282 A JP 19236282A JP S5982313 A JPS5982313 A JP S5982313A
- Authority
- JP
- Japan
- Prior art keywords
- sucrose
- aqueous solution
- oligosaccharide
- agent
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 25
- 229930006000 Sucrose Natural products 0.000 claims abstract description 20
- 239000005720 sucrose Substances 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 7
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 6
- 239000008188 pellet Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 235000000346 sugar Nutrition 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 7
- 125000000185 sucrose group Chemical group 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 13
- 150000001720 carbohydrates Chemical class 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000001990 intravenous administration Methods 0.000 abstract description 5
- 230000003405 preventing effect Effects 0.000 abstract description 4
- 229930091371 Fructose Natural products 0.000 abstract description 2
- 239000005715 Fructose Substances 0.000 abstract description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 2
- 201000001421 hyperglycemia Diseases 0.000 abstract description 2
- 235000012054 meals Nutrition 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 150000002232 fructoses Chemical class 0.000 abstract 1
- 230000003516 hyperlipidaemic effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ABXYOVCSAGTJAC-JGWLITMVSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanethial Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=S ABXYOVCSAGTJAC-JGWLITMVSA-N 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 108010042889 Inulosucrase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19236282A JPS5982313A (ja) | 1982-11-04 | 1982-11-04 | 体内脂質減少剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19236282A JPS5982313A (ja) | 1982-11-04 | 1982-11-04 | 体内脂質減少剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5982313A true JPS5982313A (ja) | 1984-05-12 |
| JPS6260369B2 JPS6260369B2 (enExample) | 1987-12-16 |
Family
ID=16290014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19236282A Granted JPS5982313A (ja) | 1982-11-04 | 1982-11-04 | 体内脂質減少剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5982313A (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005247752A (ja) * | 2004-03-04 | 2005-09-15 | Hokuren Federation Of Agricult Coop:The | 血中コレステロール上昇抑制剤 |
| JP2012176907A (ja) * | 2011-02-25 | 2012-09-13 | Glico Dairy Products Co Ltd | フラクトオリゴ糖を有効成分とするミオシン軽鎖脱リン酸化促進剤、疾患の予防又は治療剤、及び飲食品 |
| WO2021015107A1 (ja) * | 2019-07-19 | 2021-01-28 | 株式会社明治 | 組成物 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101652147B (zh) | 2007-04-03 | 2013-07-24 | 田边三菱制药株式会社 | 二肽基肽酶iv抑制化合物和甜味剂的并用 |
-
1982
- 1982-11-04 JP JP19236282A patent/JPS5982313A/ja active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005247752A (ja) * | 2004-03-04 | 2005-09-15 | Hokuren Federation Of Agricult Coop:The | 血中コレステロール上昇抑制剤 |
| JP2012176907A (ja) * | 2011-02-25 | 2012-09-13 | Glico Dairy Products Co Ltd | フラクトオリゴ糖を有効成分とするミオシン軽鎖脱リン酸化促進剤、疾患の予防又は治療剤、及び飲食品 |
| WO2021015107A1 (ja) * | 2019-07-19 | 2021-01-28 | 株式会社明治 | 組成物 |
| JP2021017414A (ja) * | 2019-07-19 | 2021-02-15 | 株式会社明治 | 組成物 |
| JP2024015186A (ja) * | 2019-07-19 | 2024-02-01 | 株式会社明治 | 組成物 |
| US12370224B2 (en) | 2019-07-19 | 2025-07-29 | Meiji Co., Ltd. | Composition containing propionibacterium freudenreichii and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6260369B2 (enExample) | 1987-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5284097B2 (ja) | 抗肥満組成物 | |
| KR100930580B1 (ko) | 다물린 에이 및 다물린 비 함량이 증가된 신규 돌외추출물의 제조방법 및 이를 이용한 대사질환 치료용 약학 조성물 | |
| EP0798971B1 (en) | Increasing creatine and glycogen concentration in muscle | |
| JP5421512B2 (ja) | Ｄ−プシコースの血糖上昇抑制効果の利用 | |
| Roberts et al. | The safety and efficacy of a dietary herbal supplement and gallic acid for weight loss | |
| JP2009511468A5 (enExample) | ||
| US20130131025A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and food or beverage | |
| ES2404694T3 (es) | Composición de manano oligosacárido para la reducción de grasa corporal | |
| JP2005513107A (ja) | （−）−ヒドロキシクエン酸、クロム、およびギムネマ酸を含有する組成物、および健常体重を促進する方法と関連する健康因子を改善する方法 | |
| KR100750988B1 (ko) | 천연물유래 진세노사이드를 포함하는 당뇨 또는혈당조절이상의 예방 또는 치료용 약학 조성물 | |
| CN111132674A (zh) | 治疗方法 | |
| US20090227514A1 (en) | Method and composition using irvingia gabonensis for reducing body weight | |
| KR970011070B1 (ko) | 과콜레스테린혈증 치료용 혼합 조성물 | |
| US5447917A (en) | D-tagatose as anti-hyperglycemic agent | |
| JPWO2007114499A1 (ja) | 抗脂肪蓄積用組成物 | |
| Buckley et al. | Serum triglyceride: method of estimation and levels in normal humans | |
| JPS5982313A (ja) | 体内脂質減少剤 | |
| Powell-Jackson | Interaction between azapropazone and warfarin | |
| EP1690519A1 (en) | Alpha-glucosidase activity inhibitor | |
| FR2628321A1 (fr) | Medicament pour le traitement de l'osteoporose | |
| CN112384079A (zh) | 用于治疗腹泻的营养组合物、其制备和治疗方法 | |
| Smith, CJ, Rosman, MS, Levitt, NS & Jackson | Guar biscuits in the diabetic diet | |
| WO2003011263A2 (de) | Verwendung eines lactatsalzes zur behandlung und prophylaxe der atherosklerose | |
| KR100573591B1 (ko) | 비만치료ㆍ억제용 맥문동 추출물 | |
| Balasubramaniam et al. | Studies on the effect of Gymnema sylvestre on diabetics |